

# **BMI CHART**

Miranandani Fortis Hospital Mira Seashore Road,

Sector 10 - A, Vashl, Navi Mumbai - 400 703. Tel.: +91-22-3919 9222 Fax: +91-22-3919 9220/21 Email: vashi@vashihospiial.com

81011	()	e E	Joint	at /a	~~\·		()	Cr	1	\//c	daht	(kas	)·	60	.31	9		BMI:		Ξ.				
<u> </u>			neigi	11 (01	1		9			- * * *	giiic	90	/			/			10			7		
Spos	7		0	1 8	1							4				e								
Puls	e	9	6 (	ופו	W	41					N-SEN	2 200	222			in a	400	405	400	405	200	205	245	215
VEIGHT lbs	100	105	100	115	120	125	130	135	140	145	150.	155	160	165	170	175	180	84 1	190	195		93.2	1011111	CONTRACTOR OF THE PARTY OF THE
kgs	45.5				12	1.000			03.6	110	THE PERSON NAMED IN				11,0	12.0		84.1		even e	2/11	remely		
IGHT In/cm		CT-5000-		yht					-	- 1							Oltes							
" - 152.4	19	20	2.	22	23	24	25	26	27	2.8	29	39	31	32	33	34		36		38	39	Name of the last	41	42
" - 154.9														31	37	3.5	34		36	-				40
- 157.4									25							SERVICE DE		13		35	36		38	38
- 160.0	17													29						34 *	35	36	-	Mart
- 192.5	17	18	18	19	20									28						33	34	35	and a	37
- 185.1	16	17	18	19	20	20	21	1	23		I .	A STATE OF THE PARTY OF THE PAR			28	-		30	100	Secretary of	and the	34	35	A. Care
- 167.6	16	17	17	18		20			22	00-100-00	Property of the last	21	11	26	51	28	-	WHITE ST	30		32.	33	34	34
- 175	15	18	17	18		19								25				ill.	29	30	31	32		33
172.7	15	13	16	17	18	19	19							25						29	30	31	32	
- 175.2	14	15	16	17	17	18	19							24						28			31	
* - 177.8	14	15	15	16	17	18	18	19	20					23					-	0		29	30	-
" - 180.3	14	14	15	16	16	17	18	18	19									2.				181		30
- 182.8	13	14	14	15	16	17	17	18	19									25				-	-	28
- 1334	13	13	14	15	15	16	17	17	18	A Company of the last	28.0	4	1	1	-	_	-	24		25		Total I	Section.	28
18 9	12	13	14	14	15	16	16	17	18	18				21				1	1-	1	25	-	27	100
- 190.1	12	13	13	14	15	15	16	16	17	18	18											25		26
- 193.0	12	12	13	14	14	15	15	16	17	17	18	18	19	20	20	21	22	22	23	23	24	25	25	1120
1 - 1111-	, <del>1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1</del>		()11000000		į.																			

-	*****	Classina	-
		Signature	

Hiranandani Healthcare Pvt. Ltd.

Mini Sea Shore Road, Sector 10 -A, Vashi, Navi Mumbai - 400703

Board Line: 022 - 39199222 | Fax: 022 - 39199220

Emergency: 022 - 39199100 | Ambulance: 1255 For Appointment: 022 - 39199222 | Health Checkup: 022 - 39199300

www.fortishealthcare.com | CIN: U85100MH2005PTC154823

GST IN: 27AABCH5894D1ZG | PAN NO: AABCH5894D





(A 11 Fortis Network Hospital)

UHID	12814759	Date	11/11/2	023	
Name	Mr. Karan Lakavath	Sex	Male	Age	31
OPD	Opthal 14	Healt	h Check-	ир	

Drug allergy: -> Not know.

Sys illness: -, No.

Hiranandani Healthcare Pvt. Ltd.

Mini Sea Shore Road, Sector 10 - A, Vashi, Navi Mumbai - 400703 Board Line: 022 - 39199222 | Fax: 022 - 39199220 Emergency: 022 - 39199100 | Ambulance: 1255

For Appointment: 022 - 39199222 | Health Checkup: 022 - 39199300

www.fortishealthcare.com |

CIN: U85100MH2005PTC154823

**UHID** 

Name

OPD

GST IN: 27AABCH5894D1ZG | PAN NO: AABCH5894D

12814759

Dental 12

Mr. Karan Lakavath





Date	11/11/2	023		
------	---------	-----	--	--

Drug allergy: Sys illness:

Health Check-up

Salvey, &





6.8 - 10.9



PATIENT NAME: MR.KARAN LAKAVATH

CODE/NAME & ADDRESS : C000045507

FORTIS VASHI-CHC -SPLZD FORTIS HOSPITAL # VASHI,

MUMBAI 440001

REF. DOCTOR :

ACCESSION NO: 0022WK002169 : FH.12814759 PATIENT ID

CLIENT PATIENT ID: UID:12814759 .

ABHA NO

Male :31 Years AGE/SEX :11/11/2023 09:01:00

RECEIVED : 11/11/2023 09:01:20 REPORTED :11/11/2023 14:08:23

### CLINICAL INFORMATION:

UID:12814759 REQNO-1605103

CORP-OPD

BILLNO-1501230PCR064255 BILLNO-1501230PCR064255

3ILLNO-1501230PCR0	64255	- 11-	Biological Reference I	nterval Units
Test Report Status	Final	Results	D. C. C. J.	
	LI/	LEMATOLOGY - CBC		
CBC-5, EDTA WHOL	E BLOOD			
	TA WHOLE BLOOD	16.3	13.0 - 17.0	g/dL
HEMOGLOBIN (HB) METHOD : SLS METHOD RED BLOOD CELL (		5.52 High	4.5 - 5.5	mil/µL
METHOD: HYDRODYNAMI	C FOCUSING	5.93	4.0 - 10.0	thou/µL
WHITE BLOOD CEL METHOD : FLUORESCENCE PLATELET COUNT	E FLOW CYTOMETRY	210	150 - 410	thou/µL
METHOD: HYDRODYNAMI	C FOCUSING BY DC DETECTION			
RBC AND PLATELE	T INDICES		40.0 - 50.0	%
HEMATOCRIT (PC)	/)	48.4	40.0 - 30.0	
METHOD : CUMULATIVE F	PULSE HEIGHT DETECTION METHOD  _AR VOLUME (MCV)	87.7	83.0 - 101.0	fL
METHOD . CALCULATED	PARAMETER LAR HEMOGLOBIN (MCH)	29.5	27.0 - 32.0	pg
METHOD : CALCULATED	PARAMETER	33.7	31.5 - 34.5	g/dL
CONCENTRATION	LAR HEMOGLOBIN (MCHC)	2145750000	2222 44.0	%
METHOD : CALCULATED RED CELL DISTRI	BUTION WIDTH (RDW)	11.6	11.6 - 14.0	70
MENTZER INDEX		15.9		
	DARAMETER			fl.

9.2

### WBC DIFFERENTIAL COUNT

METHOD: CALCULATED PARAMETER

MEAN PLATELET VOLUME (MPV) METHOD: CALCULATED PARAMETER

Dr. Akshay Dhotre, MD (Reg,no. MMC 2019/09/6377) Consultant Pathologist



Page 1 C





Email: -

Agilus Diagnostics Ltd. Hiranandani Hospital-Vashi, Mini Seashore Road, Sector 10, Navi Mumbai, 400703 Maharashtra, India Tel: 022-39199222,022-49723322, CIN - U74899PB1995PLC045956



fL









CODE/NAME & ADDRESS : C000045507

FORTIS VASHI-CHC -SPLZD FORTIS HOSPITAL # VASHI,

MUMBAI 440001

REF. DOCTOR:

ACCESSION NO: 0022WK002169 : FH.12814759 PATIENT ID

CLIENT PATIENT ID: UID:12814759

ABHA NO

Male :31 Years AGE/SEX :11/11/2023 09:01:00 DRAWN

RECEIVED : 11/11/2023 09:01:20 REPORTED :11/11/2023 14:08:23

### CLINICAL INFORMATION:

UID:12814759 REQNO-1605103

CORP-OPD

BILLNO-1501230PCR064255

BILLNO-1501230PCR064255	Biological Reference Interval Uni		
Test Report Status <u>Final</u>	Results	Biological Reference 2715	
NEUTROPHILS	57	40.0 - 80.0	%
METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING LYMPHOCYTES	31	20.0 - 40.0	%
METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING MONOCYTES	10	2.0 - 10.0	%
METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING FOSINOPHILS	2	1 - 6	%
METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING BASOPHILS	0	0 - 2	%
METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING ABSOLUTE NEUTROPHIL COUNT	3.38	2.0 - 7.0	thou/µL
METHOD: CALCULATED PARAMETER ABSOLUTE LYMPHOCYTE COUNT	1.84	1.0 - 3.0	thou/µL
METHOD: CALCULATED PARAMETER ABSOLUTE MONOCYTE COUNT	0.59	0.2 - 1.0	thou/µL
METHOD : CALCULATED PARAMETER ABSOLUTE EOSINOPHIL COUNT	0.12	0.02 - 0.50	thou/μL
METHOD: CALCULATED PARAMETER ABSOLUTE BASOPHIL COUNT	0 Low	0.02 - 0.10	thou/μL
METHOD: CALCULATED PARAMETER NEUTROPHIL LYMPHOCYTE RATIO (NLR) METHOD: CALCULATED	1.8		

### MORPHOLOGY

METHOD: MICROSCOPIC EXAMINATION

**WBC** 

METHOD: MICROSCOPIC EXAMINATION

**PLATELETS** 

METHOD: MICROSCOPIC EXAMINATION

PREDOMINANTLY NORMOCYTIC NORMOCHROMIC

NORMAL MORPHOLOGY

**ADEQUATE** 

Dr. Akshay Dhotre, MD (Reg,no. MMC 2019/09/6377) **Consultant Pathologist** 





Page 2 O



Hiranandani Hospital-Vashi, Mini Seashore Road, Sector 10, Navi Mumbai, 400703 Agilus Diagnostics Ltd. Maharashtra, India Tel: 022-39199222,022-49723322, CIN - U74899PB1995PLC045956 Email: -











CODE/NAME & ADDRESS : C000045507

FORTIS VASHI-CHC -SPLZD FORTIS HOSPITAL # VASHI,

MUMBAI 440001

REF. DOCTOR:

ACCESSION NO: 0022WK002169 : FH.12814759 PATIENT ID

CLIENT PATIENT ID: UID:12814759

ABHA NO

Male :31 Years AGE/SEX

:11/11/2023 09:01:00 DRAWN

RECEIVED : 11/11/2023 09:01:20 REPORTED: 11/11/2023 14:08:23

### CLINICAL INFORMATION:

UID:12814759 REQNO-1605103 CORP-OPD BILLNO-1501230PCR064255 BILLNO-1501230PCR064255

**Test Report Status** 

**Final** 

Results

Biological Reference Interval

Units

Interpretation(s)
RBC AND PLATELET INDICES-Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(>13)

RBC AND PLATELET INDICES-Mentzer index (MCV/RBC) is an automated cell-counter based correlation and suspicion. Estimation of HbA2 remains the gold standard for (<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for diagnosing a case of beta thalassaemia trait.

WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID showed a prognostic possibility of clinical symptoms to change from mild threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild threshold of 3.3 for NLR showed a prognostic possibility o

Dr. Akshay Dhotre, MD (Reg,no. MMC 2019/09/6377) **Consultant Pathologist** 



Page 3 Of 1

PERFORMED AT :

Agilus Diagnostics Ltd. Hiranandani Hospital-Vashi, Mini Seashore Road, Sector 10, Navi Mumbai, 400703 Maharashtra, India

Tel: 022-39199222,022-49723322, CIN - U74899PB1995PLC045956









REF. DOCTOR:



PATIENT NAME: MR.KARAN LAKAVATH

CODE/NAME & ADDRESS : C000045507

FORTIS VASHI-CHC -SPLZD FORTIS HOSPITAL # VASHI, MUMBAI 440001

ACCESSION NO: 0022WK002169

PATIENT ID : FH.12814759

CLIENT PATIENT ID: UID:12814759 ABHA NO

AGE/SEX :31 Years Male

:11/11/2023 09:01:00 DRAWN RECEIVED: 11/11/2023 09:01:20

REPORTED :11/11/2023 14:08:23

### CLINICAL INFORMATION:

UID:12814759 REQNO-1605103 CORP-OPD BILLNO-1501230PCR064255 BILLNO-1501230PCR064255

Units Biological Reference Interval Results Test Report Status Final

HAEMATOLOGY

ERYTHROCYTE SEDIMENTATION RATE (ESR), WHOLE BLOOD

E.S.R

0 - 14

mm at 1 hr

METHOD : WESTERGREN METHOD

GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD

HBA1C

5 2

Non-diabetic: < 5.7 Pre-diabetics: 5.7 - 6.4

Diabetics: > or = 6.5Therapeutic goals: < 7.0 Action suggested: > 8.0 (ADA Guideline 2021)

METHOD: HB VARIANT (HPLC)

ESTIMATED AVERAGE GLUCOSE(EAG) METHOD: CALCULATED PARAMETER

102.5

< 116.0

mg/dL

%

Interpretation(s)

ERYTHROCYTE SEDIMENTATION RATE (ESR), WHOLE BLOOD-TEST DESCRIPTION:

ERYTHROCYTE SEDIMENTATION RATE (ESR), WHOLE BLOOD-TEST DESCRIPTION:

Erythrocyte sedimentation rate (ESR) is a test that indirectly measures the degree of inflammation present in the body. The test actually measures the rate of fall Erythrocyte sedimentation of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that (sedimentation) of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that are present at the top portion of the tube after one hour. Nowadays fully automated instruments are available to measure ESR.

ESR is not diagnostic; it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an inflammatory condition. CRP is superior to ESR because it is more sensitive and reflects a more rapid change.

Increase in: Infections, Vasculities, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue injury, Pregnancy,

Estrogen medication, Aging.

Finding a very accelerated ESR(>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias, Finding a very accelerated ESR(>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias, Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocarditis).

Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocarditis).

In pregnancy BR in first trinseser: is 0-48 mm/hr(52 if anemic) and in second trimester (0-70 mm/hr(95 if anemic)). ESR returns to normal 4th week post partum.

Decreased in: Polycythermia vera, Sickle cell anemia

False elevated ESR: Increased fibrinogen, Drugs(Vitamin A, Dextran etc.), Hypercholesterolemia
False Decreased: Poikilocytosis, (SickleCells, spherocytes), Microcytosis, Low fibrinogen, Very high WBC counts, Drugs(Quinine, salicylates)

Aphoto

Dr. Akshay Dhotre, MD (Reg,no. MMC 2019/09/6377) **Consultant Pathologist** 



Page 4 Of 1

### PERFORMED AT :

Agilus Diagnostics Ltd. Hiranandani Hospital-Vashi, Mini Seashore Road, Sector 10, Navi Mumbai, 400703 Maharashtra, India

Tel: 022-39199222,022-49723322, CIN - U74899PB1995PLC045956











CODE/NAME & ADDRESS : C000045507

FORTIS VASHI-CHC -SPLZD FORTIS HOSPITAL # VASHI,

MUMBAI 440001

REF. DOCTOR: ACCESSION NO: 0022WK002169

: FH.12814759 PATIENT ID

CLIENT PATIENT ID: UID:12814759

ABHA NO

AGE/SEX :31 Years Male

:11/11/2023 09:01:00

RECEIVED: 11/11/2023 09:01:20 REPORTED :11/11/2023 14:08:23

### CLINICAL INFORMATION:

UID:12814759 REQNO-1605103 CORP-OPD BILLNO-1501230PCR064255 BILLNO-1501230PCR064255

**Test Report Status** 

**Final** 

Results

**Biological Reference Interval** 

Units

REFERENCE

1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition; 2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin; 3. The reference for the adult reference range is "Practical Haematology by Dacie and Lewis, 10th edition.

GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD-Used For:

1. Evaluating the long-term control of blood glucose concentrations in diabetic patients.

1. Evaluating the long-term control of blood glucose concentrations in diabetes.
2. Diagnosing diabetes.
3. Identifying patients at increased risk for diabetes (prediabetes).
The ADA recommends measurement of HbA1c (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients) to determine whether a patients metabolic control has remained continuously within the target range.
1. eAG (Estimated average glucose) converts percentage HbA1c to md/dl, to compare blood glucose levels.
2. eAG gives an evaluation of blood glucose levels for the last couple of months.
3. eAG is calculated as eAG (mg/dl) = 28.7 \* HbA1c - 46.7

HbA1c Estimation can get affected due to:

1. Shortened Erythrocyte survival: Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g. recovery from acute blood loss, hemolytic anemia) will falsely lower HbA1c test results. Fructosamine is recommended in these patients to which indicates diabetes control over 15 days.

2. Vitamin C & E are reported to falsely lower test results. (possibly by inhibiting glycation of hemoglobin.

3. Iron deficiency anemia is reported to increase test results. Hypertriglyceridemia, uremia, hyperbilirubinemia, chronic alcoholism, chronic ingestion of salicylates & opiates addiction are reported to interfere with some assay methods, falsely increasing results.

4. Interference of hemoglobinopathies in HbA1c estimation is seen in

a) Homozygous hemoglobinopathy. Fructosamine is recommended for testing of HbA1c.
b) Heterozygous state detected (D10 is corrected for HbS & HbC trait.)
c) HbF > 25% on alternate paltform (Boronate affinity chromatography) is recommended for testing of HbA1c.Abnormal Hemoglobin electrophoresis (HPLC method) is recommended for detecting a hemoglobinopathy

politica

Dr. Akshay Dhotre, MD (Reg,no. MMC 2019/09/6377) **Consultant Pathologist** 





Page 5 Of 17

View Details



Agilus Diagnostics Ltd. Hiranandani Hospital-Vashi, Mini Seashore Road, Sector 10, Navi Mumbai, 400703

Maharashtra, India Tel: 022-39199222,022-49723322, CIN - U74899PB1995PLC045956









REF. DOCTOR :



Male

PATIENT NAME: MR.KARAN LAKAVATH

CODE/NAME & ADDRESS : C000045507

FORTIS VASHI-CHC -SPLZD FORTIS HOSPITAL # VASHI, MUMBAI 440001 ACCESSION NO: 0022WK002169

PATIENT ID : FH.12814759 CLIENT PATIENT ID: UID:12814759

ABHA NO

9 AGE/SEX :31 Years

DRAWN :11/11/2023 09:01:00

RECEIVED : 11/11/2023 09:01:20 REPORTED :11/11/2023 14:08:23

### CLINICAL INFORMATION:

UID:12814759 REQNO-1605103 CORP-OPD BILLNO-1501230PCR064255 BILLNO-1501230PCR064255

**Test Report Status** 

Final

Results

Biological Reference Interval

Units

### **IMMUNOHAEMATOLOGY**

### ABO GROUP & RH TYPE, EDTA WHOLE BLOOD

**ABO GROUP** 

TYPE O

METHOD: TUBE AGGLUTINATION RH TYPE
METHOD: TUBE AGGLUTINATION

POSITIVE

Interpretation(s)
ABO GROUP & RH TYPE, EDTA WHOLE BLOOD-Blood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface of red blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A,B,O or AB.

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for availability of the same."

The test is performed by both forward as well as reverse grouping methods.

(KONA)

Dr. Akshay Dhotre, MD (Reg,no. MMC 2019/09/6377) Consultant Pathologist



Page 6 Of 17

View Details

View Report

PERFORMED AT :

Agilus Diagnostics Ltd. Hiranandani Hospital-Vashi, Mini Seashore Road, Sector 10, Navi Mumbai, 400703 Maharashtra, India

Tel: 022-39199222,022-49723322, CIN - U74899PB1995PLC045956







REF. DOCTOR:



PATIENT NAME: MR.KARAN LAKAVATH

CODE/NAME & ADDRESS : C000045507

FORTIS VASHI-CHC -SPLZD FORTIS HOSPITAL # VASHI, MUMBAI 440001

ACCESSION NO : 0022WK002169 PATIENT ID : FH.12814759

CLIENT PATIENT ID: UID:12814759

ABHA NO

AGE/SEX :31 Years Male :11/11/2023 09:01:00 DRAWN

RECEIVED : 11/11/2023 09:01:20 REPORTED :11/11/2023 14:08:23

### CLINICAL INFORMATION:

UID:12814759 REQNO-1605103

CORP-OPD

BILLNO-1501230PCR064255

Test Report Status <u>Final</u>	Results	Biological Reference Inter	rval Units
	BIOCHEMISTRY		
IVER FUNCTION PROFILE, SERUM			
BILIRUBIN, TOTAL	0.61	0.2 - 1.0	mg/dL
METHOD: JENDRASSIK AND GROFF BILIRUBIN, DIRECT	0.15	0.0 - 0.2	mg/dL
METHOD: JENDRASSIK AND GROFF SILIRUBIN, INDIRECT	0.46	0.1 - 1.0	mg/dL
METHOD : CALCULATED PARAMETER OTAL PROTEIN	7.9	6.4 - 8.2	g/dL
METHOD: BIURET ALBUMIN	4.3	3.4 - 5.0	g/dL
METHOD : BCP DYE BINDING GLOBULIN	3.6	2.0 - 4.1	g/dL
METHOD : CALCULATED PARAMETER ALBUMIN/GLOBULIN RATIO	1.2	1.0 - 2.1	RATIO
METHOD : CALCULATED PARAMETER ASPARTATE AMINOTRANSFERASE(AST/SGO)	r) 23	15 - 37	U/L
METHOD: UV WITH P5P ALANINE AMINOTRANSFERASE (ALT/SGPT)	29	< 45.0	U/L
METHOD: UV WITH P5P ALKALINE PHOSPHATASE	94	30 - 120	U/L
METHOD : PNPP-ANP GAMMA GLUTAMYL TRANSFERASE (GGT)	39	15 - 85	U/L
METHOD : GAMMA GLUTAMYLCARBOXY 4NITROANILIDE LACTATE DEHYDROGENASE	137	85 - 227	U/L
METHOD : LACTATE -PYRUVATE			
GLUCOSE FASTING, FLUORIDE PLASMA		Named - 4100	mg/dL
FBS (FASTING BLOOD SUGAR)	94	Normal : < 100 Pre-diabetes: 100-125 Diabetes: >/=126	mg/dL

ADDITION

METHOD: HEXOKINASE

Dr. Akshay Dhotre, MD (Reg,no. MMC 2019/09/6377) Consultant Pathologist

View Details



Page 7 Of 17



Agilus Diagnostics Ltd. Hiranandani Hospital-Vashi, Mini Seashore Road, Sector 10, Navi Mumbai, 400703

Maharashtra, India Tel: 022-39199222,022-49723322, CIN - U74899PB1995PLC045956









Male

PATIENT NAME: MR.KARAN LAKAVATH

CODE/NAME & ADDRESS : C000045507

FORTIS VASHI-CHC -SPLZD FORTIS HOSPITAL # VASHI,

MUMBAI 440001

REF. DOCTOR:

ACCESSION NO: 0022WK002169

PATIENT ID : FH.12814759 CLIENT PATIENT ID: UID:12814759

ABHA NO

AGE/SEX :31 Years

:11/11/2023 09:01:00 DRAWN RECEIVED: 11/11/2023 09:01:20

REPORTED: 11/11/2023 14:08:23

#### CLINICAL INFORMATION:

UID:12814759 REQNO-1605103

CORP-OPD

BILLNO-1501230PCR064255 BILLNO-1501230PCR064255

**Test Report Status** 

Results

Biological Reference Interval

Units

### **KIDNEY PANEL - 1**

BLOOD UREA NITROGEN (BUN), SERUM

**BLOOD UREA NITROGEN** 

METHOD: UREASE - UV

#### CREATININE EGFR- EPI

CREATININE

METHOD: ALKALINE PICRATE KINETIC JAFFES

AGE

31

0.95

7

0.90 - 1.30

6 - 20

mg/dL

mg/dL

years

GLOMERULAR FILTRATION RATE (MALE)

METHOD: CALCULATED PARAMETER

109.74

Refer Interpretation Below

mL/min/1.73m2

### **BUN/CREAT RATIO**

BUN/CREAT RATIO

METHOD: CALCULATED PARAMETER

7.37

5.00 - 15.00

URIC ACID, SERUM

URIC ACID

METHOD : URICASE UV

4.4

3.5 - 7.2

mg/dL

TOTAL PROTEIN, SERUM

TOTAL PROTEIN

METHOD : BTURET

7.9

6.4 - 8.2

g/dL

( Kolutin

Dr. Akshay Dhotre, MD (Reg,no. MMC 2019/09/6377) **Consultant Pathologist** 



Page 8 Of 17

View Details



Agilus Diagnostics Ltd. Hiranandani Hospital-Vashi, Mini Seashore Road, Sector 10, Navi Mumbai, 400703 Maharashtra, India

Tel: 022-39199222,022-49723322, CIN - U74899PB1995PLC045956











CODE/NAME & ADDRESS : C000045507

FORTIS VASHI-CHC -SPLZD FORTIS HOSPITAL # VASHI,

MUMBAI 440001

REF. DOCTOR:

ACCESSION NO: 0022WK002169

: FH.12814759 PATIENT ID CLIENT PATIENT ID: UID:12814759

ABHA NO

Male :31 Years AGE/SEX

:11/11/2023 09:01:00 DRAWN RECEIVED: 11/11/2023 09:01:20

REPORTED: 11/11/2023 14:08:23

### CLINICAL INFORMATION :

UID:12814759 REQNO-1605103

CORP-OPD

BILLNO-1501230PCR064255

ILLNO-1501230PCR064255 est Report Status <u>Final</u>	Results		Biological Reference	Interval Units
ALBUMIN, SERUM ALBUMIN METHOD: BCP DYE BINDING	4.3		3.4 - 5.0	g/dL
GLOBULIN GLOBULIN METHOD: CALCULATED PARAMETER	3.6	Į,	2.0 - 4.1	g/dL
ELECTROLYTES (NA/K/CL), SERUM SODIUM, SERUM	135 Low		136 - 145	mmol/l
METHOD: ISE INDIRECT POTASSIUM, SERUM	4.49		3.50 - 5.10	mmol/
METHOD: ISE INDIRECT CHLORIDE, SERUM METHOD: ISE INDIRECT	100		98 - 107	mmol/

### Interpretation(s)

Interpretation(s)
LIVER FUNCTION PROFILE, SERUMBilirubin is a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give
Bilirubin is a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels results from increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg, yellow discoloration in jaundice. Elevated more than unconjugated obstruction and hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin when (indirect) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin there is some kind of blockage of the bile ducts like in Gallstones getting into the bile ducts, tumors &Scarring of the bile ducts. Increased unconjugated (indirect) bilirubin may be a result of Hemolytic or pernicious anemia, Transfusion reaction & a common metabolic condition termed Gilbert syndrome, due to low levels of the enzyme that attaches sugar molecules to bilirubin.

Ashata

Dr. Akshay Dhotre, MD (Reg,no. MMC 2019/09/6377) **Consultant Pathologist** 





Page 9 Of 1

View Details

View Report

### PERFORMED AT:

Agrius Diagnostics Ltd.
Hiranandani Hospital-Vashi, Mini Seashore Road, Sector 10,
Navi Mumbai, 400703
Maharashtra, India
Tel: 022-39199222,022-49723322,
CIN - U74899PB1995PLC045956 Agilus Diagnostics Ltd.

Fmail: -











CODE/NAME & ADDRESS : C000045507

FORTIS VASHI-CHC -SPLZD FORTIS HOSPITAL # VASHI,

MUMBAI 440001

REF. DOCTOR :

ACCESSION NO : 0022WK002169

PATIENT ID : FH.12814759 CLIENT PATIENT ID: UID:12814759

ABHA NO

Male :31 Years AGE/SEX

:11/11/2023 09:01:00 DRAWN RECEIVED: 11/11/2023 09:01:20

REPORTED :11/11/2023 14:08:23

### CLINICAL INFORMATION:

UID:12814759 REQNO-1605103 CORP-OPD BILLNO-1501230PCR064255 BILLNO-1501230PCR064255

**Test Report Status** 

Final

Results

Biological Reference Interval

Units

AST is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measured clinically as a marker for liver health. AST levels increase during chronic viral hepatitis, blockage of the bile duct, cirrhosis of the liver,liver cancer, kidney failure, hemolytic anemia, pancreatitis, hemochromatosis. AST levels may also increase after a heart attack or strenuous activity. ALT test measures the amount of this enzyme in the blood. ALT is found mainly in the liver, but also in smaller amounts in the kidneys, heart, muscles, and pancreas. It is commonly measured as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health. AST levels increase during acute hepatitis, sometimes due to a viral infection, ischemia to the liver, chronic hepatitis, obstruction of bile ducts, cirrhosis.

ALP is a postruction of bile ducts cirrhosis.

hepatitis, obstruction of bile ducts, cirrhosis.

ALP is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in Biliary obstruction, Osteoblastic bone tumors, osteomalacia, hepatitis, Hyperparathyroidism, Leukemia, Lymphoma, Pagets disease, Rickets, Sarcoidosis etc. Lower-than-normal ALP levels seen in Hypophosphatasia, Malnutrition, Protein deficiency, Wilsons disease.

GGT is an enzyme found in cell membranes of many tissues mainly in the liver, kidney and pancreas. It is also found in other tissues including intestine, spleen, heart, brain and seminal vesicles. The highest concentration is in the kidney, but the liver is considered the source of normal enzyme activity. Serum GGT has been widely used as an index of liver dysfunction. Elevated serum GGT activity can be found in diseases of the liver, biliary system and pancreas. Conditions that increase serum GGT are obstructive liver disease, high alcohol consumption and use of enzyme-inducing drugs etc.

Total Protein also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin-Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstroms disease. Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc.

Albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc.

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and sothat no glucose is excreted in the

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and sothat no glucose is excreted in the urine.

Increased in: Diabetes mellitus, Cushing's syndrome (10 – 15%), chronic pancreatitis (30%). Drugs:corticosteroids, phenytoin, estrogen, thiazides.

Decreased in: Pancreatic islet cell disease with increased insulin, insulinoma, adrenocortical insufficiency, hypopituitarism, diffuse liver disease, palactosemia), Drugs-insulin, ethanol, propranolois, justifenylureas, tolbutamide, and other oral hypoglycemic agents.

NOTE: While random serum glucose levels correlate with home glucose monitoring results (weekly mean capillary glucose values), there is wide fluctuation within individuals. Thus, glycosylated hemoglobin (HbA1c) levels are favored to monitor glycemic control.

High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.

BLOOD UREA NITROGEN (BUN), SERIM-Causes of Increased levels include Pre renal (High protein diet, Increased protein catabolism, GI haemorrhage, Cortisol, Dehydration, CHF Renal), Renal Failure, Post Renal (Malignancy, Nephrolithiasis, Prostatism)

Causes of decreased level include Liver disease, SIADH.

CREATINITE EGFR- EPT- Kidney disease outcomes quality initiative (KDOQI) guidelines state that estimation of GFR is the best overall indices of the Kidney function.

- It gives a rough measure of number of functioning nephrons. Reduction in GFR implies progression of underlying disease.

- The GFR is a calculation based on serum creatinine test.

- Creatinine is mainly derived from the metabolism of creatine in muscle, and its generation is proportional to the total muscle mass. As a result, mean creatinine generation is higher in men than in women, in younger than in older individuals, and i

National Kidney Foundation (NKF) and the American Society of Nephrology (ASN).

Estimated GFR Calculated Using the CKD-EPI equation-https://testguide.labmed.uw.edu/guideline/egfr
Ghuman JK, et al. Impact of Removing Race Variable on CKD Classification Using the Creatinine-Based 2021 CKD-EPI Equation. Kidney Med 2022, 4:100471. 35756325.

Harrison's Principle of Internal Medicine, 21st ed. pg 62 and 334

URIC ACID, SERUM-Causes of Increased levels:-Dietary(High Protein Intake, Prolonged Fasting, Rapid weight loss), Gout, Lesch nyhan syndrome, Type 2 DM, Metabolic syndrome Causes of decreased levels-Low Zinc intake, OCP, Multiple Sclerosis

TOTAL PROTEIN, SERUM-is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin.

Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstroms disease.

pointing

Page 10 Of 17

Dr. Akshay Dhotre, MD (Reg,no. MMC 2019/09/6377) Consultant Pathologist







Email: -

Agilus Diagnostics Ltd. Hiranandani Hospital-Vashi, Mini Seashore Road, Sector 10, Navi Mumbai, 400703 Maharashtra, India Tel: 022-39199222,022-49723322, CIN - U74899PB1995PLC045956











CODE/NAME & ADDRESS : C000045507

FORTIS VASHI-CHC -SPLZD FORTIS HOSPITAL # VASHI, MUMBAI 440001

REF. DOCTOR : ACCESSION NO: 0022WK002169

: FH.12814759 PATIENT ID CLIENT PATIENT ID: UID:12814759

ABHA NO

AGE/SEX :31 Years

:11/11/2023 09:01:00 DRAWN RECEIVED : 11/11/2023 09:01:20 REPORTED :11/11/2023 14:08:23

### CLINICAL INFORMATION:

UID:12814759 REQNO-1605103 CORP-OPD BILLNO-1501230PCR064255 BILLNO-1501230PCR064255

**Test Report Status Final**  Results

Biological Reference Interval Units

Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Mainutrition, Nephrotic syndrome, Protein-losing enteropathy etc.


ALBUMIN, SERUM-Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum serum albumin is the most abundant protein in human blood plasma. It is produced in the liver, nephrotic syndrome, protein-losing enteropathy, protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, protein, Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, protein, Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, protein, Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, protein, Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, protein, Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, liver disease like cirrhosis of the liver.

(KONSTS

Dr. Akshay Dhotre, MD (Reg,no. MMC 2019/09/6377) Consultant Pathologist



Page 11



### PERFORMED AT :

Agilus Diagnostics Ltd. Hiranandani Hospital-Vashi, Mini Seashore Road, Sector 10, Navi Mumbai, 400703 Maharashtra, India Tel: 022-39199222,022-49723322,

CIN - U74899PB1995PLC045956







CODE/NAME & ADDRESS : C000045507

FORTIS VASHI-CHC -SPLZD FORTIS HOSPITAL # VASHI,

MUMBAI 440001

REF. DOCTOR :

ACCESSION NO: 0022WK002169

: FH.12814759

CLIENT PATIENT ID: UID:12814759

ABHA NO

PATIENT ID

Male AGE/SEX :31 Years :11/11/2023 09:01:00 DRAWN

RECEIVED: 11/11/2023 09:01:20

REPORTED :11/11/2023 14:08:23

### CLINICAL INFORMATION:

UID:12814759 REQNO-1605103

CORP-OPD

BILLNO-1501230PCR064255 BILLNO-1501230PCR064255

	11000	Panulto	Biological Reference Interval	Units
Test Report Status	Final	Results	Didiogram manage	

Test Report Status Final	Results	Biological Kalerana	
	BIOCHEMISTRY - LIPI	D	
LIPID PROFILE, SERUM		8. 7414	122 L Val
CHOLESTEROL, TOTAL	157	< 200 Desirable 200 - 239 Borderline High >/= 240 High	mg/dL
METHOD: ENZYMATIC/COLORIMETRIC, CHOLESTEROL OXIDAS	SE, ESTERASE, PEROXIDASE		741
TRIGLYCERIDES	102	< 150 Normal 150 - 199 Borderline High 200 - 499 High >/=500 Very High	mg/dL
METHOD: ENZYMATIC ASSAY		< 40 Low	mg/dL
HDL CHOLESTEROL	34 Low	>/=60 High	<b>3</b>
METHOD: DIRECT MEASURE - PEG LDL CHOLESTEROL, DIRECT	106	< 100 Optimal	mg/dL
<del></del>		100 - 129 Near or above optimal	
		130 - 159 Borderline High 160 - 189 High >/= 190 Very High	
METHOD: DIRECT MEASURE WITHOUT SAMPLE PRETREATME	NT	n : 11 - 1 than 120	mg/dL
NON HDL CHOLESTEROL	123	Desirable: Less than 130 Above Desirable: 130 - 15 Borderline High: 160 - 189 High: 190 - 219 Very high: > or = 220	9
METHOD: CALCULATED PARAMETER VERY LOW DENSITY LIPOPROTEIN	20.4	= 30.0</td <td>mg/dL</td>	mg/dL
METHOD: CALCULATED PARAMETER	4.6 High	3.3 - 4.4 Low Risk	

4.6 High

METHOD: CALCULATED PARAMETER

CHOL/HDL RATIO

Dr. Akshay Dhotre, MD (Reg, no. MMC 2019/09/6377) **Consultant Pathologist** 

Page 12 Of 17



3.3 - 4.4 Low Risk

> 11.0 High Risk

4.5 - 7.0 Average Risk 7.1 - 11.0 Moderate Risk







Agilus Diagnostics Ltd. Hiranandani Hospital-Vashi, Mini Seashore Road, Sector 10, Navi Mumbai, 400703 Maharashtra, India Tel: 022-39199222,022-49723322, CIN - U74899PB1995PLC045956 Email: -



Diagnostics Report ADDRESS : C000045507
FORTIS VASHI-CHC -SPLZD FORTIS HOSPITAL # VASHI, MUMBAI 449001

ACCESSION NO: 0022WK002169

PATIENT ID : FH.12814759 CLIENT PATIENT ID: UID:12814759

ABHA NO

:31 Years AGE/SEX

AGE/SEX :31 Years Project Proj

REPORTED :11/11/2023 14:08:23

### CLINICAL INFORMATION:

UID:12814759 REQNO-1605103 CORP-OPD BILLNO-1501230PCR064255 BILLNO-1501230PCR064255

Test Report Status <u>Final</u> Results Biological Reference Interval Units
---

LDL/HDL RATIO

3.1 High

0.5 - 3.0 Desirable/Low Risk 3.1 - 6.0 Borderline/Moderate

Risk

REF. DOCTOR :

>6.0 High Risk

METHOD: CALCULATED PARAMETER

Interpretation(s)

MONETS

Dr. Akshay Dhotre, MD (Reg,no. MMC 2019/09/6377) **Consultant Pathologist** 





Page 13 Of 17

View Report



Agilus Diagnostics Ltd. Hiranandani Hospital-Vashi, Mini Seashore Road, Sector 10, Navi Mumbai, 400703 Maharashtra, India Tel: 022-39199222,022-49723322,

CIN - U74899PB1995PLC045956











CODE/NAME & ADDRESS : C000045507

FORTIS VASHI-CHC -SPLZD FORTIS HOSPITAL # VASHI,

MUMBAI 440001

REF. DOCTOR :

ACCESSION NO: 0022WK002169 : FH.12814759 PATIENT ID

CLIENT PATIENT ID: UID:12814759

ABHA NO

Male AGE/SEX :31 Years

:11/11/2023 09:01:00 DRAWN RECEIVED : 11/11/2023 09:01:20

REPORTED :11/11/2023 14:08:23

CLINICAL INFORMATION:

UID:12814759 REQNO-1605103 CORP-OPD

BILLNO-1501230PCR064255

BILLNO-1501230PCR064255

**Test Report Status Final** 

Biological Reference Interval Units

**CLINICAL PATH - URINALYSIS** 

Results

**KIDNEY PANEL - 1** 

PHYSICAL EXAMINATION, URINE

COLOR

APPEARANCE

PALE YELLOW

CLEAR

CHEMICAL EXAMINATION, URINE

PH

6.0

4.7 - 7.5

METHOD: REFLECTANCE SPECTROPHOTOMETRY- DOUBLE INDICATOR METHOD SPECIFIC GRAVITY

1.003 - 1.035

1.020

METHOD: REFLECTANCE SPECTROPHOTOMETRY (APPARENT PKA CHANGE OF PRETREATED POLYELECTROLYTES IN RELATION TO IONIC CONCENTRATION)

**PROTEIN** 

NOT DETECTED METHOD: REFLECTANCE SPECTROPHOTOMETRY - PROTEIN-ERROR-OF-INDICATOR PRINCIPLE NOT DETECTED

**GLUCOSE** 

NOT DETECTED

NOT DETECTED

METHOD: REFLECTANCE SPECTROPHOTOMETRY, DOUBLE SEQUENTIAL ENZYME REACTION-GOD/POD NOT DETECTED

NOT DETECTED

KETONES

METHOD: REFLECTANCE SPECTROPHOTOMETRY, ROTHERA'S PRINCIPLE

NOT DETECTED

BLOOD

NOT DETECTED

BILIRUBIN

METHOD: REFLECTANCE SPECTROPHOTOMETRY, PEROXIDASE LIKE ACTIVITY OF HAEMOGLOBIN NOT DETECTED

NOT DETECTED

METHOD: REFLECTANCE SPECTROPHOTOMETRY, DIAZOTIZATION- COUPLING OF BILIRUBIN WITH DIAZOTIZED SALT

NORMAL

UROBILINOGEN

NORMAL

NITRITE

METHOD: REFLECTANCE SPECTROPHOTOMETRY (MODIFIED EHRLICH REACTION) NOT DETECTED

NOT DETECTED

METHOD: REFLECTANCE SPECTROPHOTOMETRY, CONVERSION OF NITRATE TO NITRITE

LEUKOCYTE ESTERASE

NOT DETECTED

NOT DETECTED

MICROSCOPIC EXAMINATION, URINE

RED BLOOD CELLS

NOT DETECTED

NOT DETECTED

/HPF

Dr. Akshay Dhotre, MD (Reg,no. MMC 2019/09/6377) **Consultant Pathologist** 

Dr. Rekha Nair, MD (Reg No. MMC 2001/06/2354) Microbiologist





Page 14 Of 1


PERFORMED AT :

Agilus Diagnostics Ltd. Hiranandani Hospital-Vashi, Mini Seashore Road, Sector 10, Navi Mumbai, 400703 Maharashtra, India

Tel: 022-39199222,022-49723322, CIN - U74899PB1995PLC045956

Fmail: -









CODE/NAME & ADDRESS : C000045507

FORTIS VASHI-CHC -SPLZD FORTIS HOSPITAL # VASHI,

MUMBAI 440001

**REF. DOCTOR:** 

ACCESSION NO: 0022WK002169

PATIENT ID : FH.12814759 CLIENT PATIENT ID: UID:12814759 :

ABHA NO

AGE/SEX :31 Years DRAWN

Male :11/11/2023 09:01:00 RECEIVED : 11/11/2023 09:01:20

REPORTED :11/11/2023 14:08:23

### CLINICAL INFORMATION:

UID:12814759 REQNO-1605103 CORP-OPD BILLNO-1501230PCR064255 BILLNO-1501230PCR064255

Test Report Status Final	Results	Biological Reference	
			Interval Units
PUS CELL (WBC'S)	0-1	0-5	/UDE
PITHELIAL CELLS	1-2	0-5	/HPF
CASTS	NOT DETECTED	0-3	/HPF
CRYSTALS	NOT DETECTED		
BACTERIA METHOD: MICROSCOPIC EXAMINATION	NOT DETECTED	NOT DETECTED	
EAST	NOT DETECTED	NOT DETECTED	
REMARKS	URINARY MICROSCOP	IC EXAMINATION DONE ON LIE	RINARY
METHOD: MICROSCOPIC EXAMINATION	CENTRIFUGED SEDIM	ENT.	

### Interpretation(s)



Dr. Akshay Dhotre, MD (Reg,no. MMC 2019/09/6377) Consultant Pathologist

Dr. Rekha Nair, MD (Reg No. MMC 2001/06/2354) Microbiologist





Page 15 Of 17

View Report



PERFORMED AT :

Agilus Diagnostics Ltd. Hiranandani Hospital-Vashi, Mini Seashore Road, Sector 10, Navi Mumbai, 400703 Maharashtra, India

Tel: 022-39199222,022-49723322, CIN - U74899PB1995PLC045956





CODE/NAME & ADDRESS : C000045507

FORTIS VASHI-CHC -SPLZD FORTIS HOSPITAL # VASHI,

MUMBAI 440001

REF. DOCTOR :

ACCESSION NO: 0022WK002169

PATIENT ID : FH.12814759 CLIENT PATIENT ID: UID:12814759

ABHA NO

AGE/SEX :31 Years Male

:11/11/2023 09:01:00 DRAWN RECEIVED: 11/11/2023 09:01:20

REPORTED: 11/11/2023 14:08:23

### CLINICAL INFORMATION:

UID:12814759 REQNO-1605103 CORP-OPD BILLNO-1501230PCR064255 BILLNO-1501230PCR064255

**Test Report Status** 

Results

Biological Reference Interval Units

### SPECIALISED CHEMISTRY - HORMONE

### THYROID PANEL, SERUM

ng/dL 80.0 - 200.0 134.7 T3 METHOD: ELECTROCHEMILUMINESCENCE IMMUNOASSAY, COMPETITIVE PRINCIPLE µg/dL 5.10 - 14.10 12.35 **T4** METHOD: ELECTROCHEMILUMINESCENCE IMMUNOASSAY, COMPETITIVE PRINCIPLE µIU/mL 0.270 - 4.2001.920

TSH (ULTRASENSITIVE) METHOD: ELECTROCHEMILUMINESCENCE, SANDWICH IMMUNOASSAY

Interpretation(s)

Dr. Akshay Dhotre, MD (Reg,no. MMC 2019/09/6377) **Consultant Pathologist** 





Page 16 Of 17

PERFORMED AT :

Agilus Diagnostics Ltd. Hiranandani Hospital-Vashi, Mini Seashore Road, Sector 10, Navi Mumbai, 400703 Maharashtra, India Tel: 022-39199222,022-49723322, CIN - U74899PB1995PLC045956









CODE/NAME & ADDRESS : C000045507

FORTIS VASHI-CHC -SPLZD FORTIS HOSPITAL # VASHI, MUMBAI 440001

REF. DOCTOR :

ACCESSION NO : 0022WK002169 : FH.12814759 PATIENT ID

CLIENT PATIENT ID: UID:12814759

ABHA NO

Male AGE/SEX :31 Years

:11/11/2023 09:01:00 DRAWN RECEIVED : 11/11/2023 09:01:20

REPORTED :11/11/2023 14:08:23

### CLINICAL INFORMATION:

UID:12814759 REQNO-1605103 CORP-OPD BILLNO-1501230PCR064255 BILLNO-1501230PCR064255

**Test Report Status** 

Final

Results

Biological Reference Interval

Units

## SPECIALISED CHEMISTRY - TUMOR MARKER

## PROSTATE SPECIFIC ANTIGEN, SERUM

PROSTATE SPECIFIC ANTIGEN

0.206

0.0 - 1.4

ng/mL

METHOD: ELECTROCHEMILUMINESCENCE, SANDWICH IMMUNOASSAY

Interpretation(s)
PROSTATE SPECIFIC ANTIGEN, SERUM-- PSA is detected in the male patients with normal, benign hyperplastic and malignant prostate tissue and in patients with prostatitis.
- PSA is not detected (or detected at very low levels) in the patients without prostate tissue (because of radical prostatectomy or cystoprostatectomy) and also in the female

- PSA is not detected (or detected at very low levels) in the patients without postate cancer and it is better to be used in conjunction with other diagnostic procedures.

- It a suitable marker for monitoring of patients with Prostate Cancer and it is better to be used in conjunction with other diagnostic procedures.

- Serial PSA levels can help determine the success of prostatectomy and the need for further treatment, such as radiation, endocrine or chemotherapy and useful in detecting residual disease and early recurrence of tumor.

- Elevated levels of PSA can be also observed in the patients with non-malignant diseases like Prostatitis and Benign Prostatic Hyperplasia.

- Specimens for total PSA assay should be obtained before biopsy, prostatectomy or prostatic massage, since manipulation of the prostate gland may lead to elevated PSA - Specimens for total PSA assay should be obtained before biopsy, prostatectomy or prostatic massage, since manipulation of the prostate gland may lead to elevated PSA - Specimens for total PSA assay should be obtained before biopsy, prostatectomy or prostatic massage, since manipulation of the prostate gland may lead to elevated PSA - Specimens for total PSA screening is recommended for early detection of Prostate cancer above the age of 40 years. Following Age specific reference range can be used as a guide lines.

- Measurement of total PSA alone may not clearly distinguish between benign prostatic hyperplasia (BPH) from cancer, this is especially true for the total PSA values between 4-10 ng/mL.

petween 4-10 ng/mL.

- Total PSA values determined on patient samples by different testing procedures cannot be directly compared with one another and could be the cause of erroneous rotal PSA values determined on patient samples by different testing procedures cannot be directly compared with one another and could be the cause of erroneous rotal PSA values determined on patient samples by different testing procedures cannot be directly compared with one another and could be the cause of erroneous rotal PSA values determined on patient samples by different testing procedures cannot be directly compared with one another and could be the cause of erroneous rotal PSA values determined on patient samples by different testing procedures cannot be directly compared with one another and could be the cause of erroneous rotal PSA values determined on patient samples by different testing procedures cannot be directly compared with one another and could be the cause of erroneous rotal PSA values determined on patient samples by different testing procedures cannot be different testing procedures.

1. Burtis CA, Ashwood ER, Bruns DE. Teitz textbook of clinical chemistry and Molecular Diagnostics. 4th edition.
2. Williamson MA, Snyder LM. Wallach's interpretation of diagnostic tests. 9th edition.

\*\*End Of Report\*\*

Please visit www.agilusdiagnostics.com for related Test Information for this accession

Dr. Akshay Dhotre, MD (Reg,no. MMC 2019/09/6377) Consultant Pathologist



Page 17 Of 17

PERFORMED AT :

Agilus Diagnostics Ltd. Hiranandani Hospital-Vashi, Mini Seashore Road, Sector 10, Navi Mumbai, 400703 Maharashtra, India

Tel: 022-39199222,022-49723322, CIN - U74899PB1995PLC045956









CODE/NAME & ADDRESS : C000045507

FORTIS VASHI-CHC -SPLZD FORTIS HOSPITAL # VASHI,

MUMBAI 440001

REF. DOCTOR:

ACCESSION NO : 0022WK002179

PATIENT ID : FH.12814759 CLIENT PATIENT ID: UID:12814759

ABHA NO

AGE/SEX :31 Years Male

:11/11/2023 09:15:00 DRAWN RECEIVED : 11/11/2023 09:16:59 REPORTED: 11/11/2023 10:39:48

CLINICAL INFORMATION:

UID:12814759 REQNO-1605103

CORP-OPD

BILLNO-1501230PCR064255 BILLNO-1501230PCR064255

Test Report Status

**Final** 

Results

Biological Reference Interval Units

**CLINICAL PATH - STOOL ANALYSIS** 

STOOL: OVA & PARASITE

PHYSICAL EXAMINATION, STOOL

COLOUR

METHOD: VISUAL

CONSISTENCY

METHOD: VISUAL

MUCUS

METHOD: VISUAL VISIBLE BLOOD

METHOD : VISUAL

BROWN

WELL FORMED

NOT DETECTED

ABSENT

ABSENT

CHEMICAL EXAMINATION, STOOL

OCCULT BLOOD

METHOD: GUAIAC ACID METHOD

NOT DETECTED

NOT DETECTED

NOT DETECTED

MICROSCOPIC EXAMINATION, STOOL

**PUS CELLS** 

METHOD: MICROSCOPIC EXAMINATION

RED BLOOD CELLS

METHOD: MICROSCOPIC EXAMINATION

CYSTS

METHOD: MICROSCOPIC EXAMINATION

OVA

METHOD: MICROSCOPIC EXAMINATION

LARVAE

METHOD: MICROSCOPIC EXAMINATION

TROPHOZOITES

METHOD: MICROSCOPIC EXAMINATION

0-1

NOT DETECTED

Rucha. N

Dr. Rekha Nair, MD (Reg No. MMC 2001/06/2354) Microbiologist



Page 1 Of 2

View Report

PERFORMED AT :

Agilus Diagnostics Ltd. Hiranandani Hospital-Vashi, Mini Seashore Road, Sector 10, Navi Mumbai, 400703

Maharashtra, India

Tel: 022-39199222,022-49723322, CIN - U74899PB1995PLC045956

Email: -



/hpf

/HPF







CODE/NAME & ADDRESS : C000045507

FORTIS VASHI-CHC -SPLZD FORTIS HOSPITAL # VASHI,

MUMBAI 440001

REF. DOCTOR :

ACCESSION NO: 0022WK002179 : FH.12814759 PATIENT ID

CLIENT PATIENT ID: UID:12814759 1

ABHA NO

Male AGE/SEX :31 Years

:11/11/2023 09:15:00 RECEIVED : 11/11/2023 09:16:59

REPORTED :11/11/2023 10:39:48

## CLINICAL INFORMATION:

UID:12814759 REQNO-1605103 CORP-OPD BILLNO-1501230PCR064255 BILLNO-1501230PCR064255

**Test Report Status** 

**Final** 

Results

Biological Reference Interval

Units

Interpretation(s)

\*\*End Of Report\*\*

Please visit www.agilusdiagnostics.com for related Test Information for this accession

Dr. Rekha Nair, MD (Reg No. MMC 2001/06/2354) Microbiologist

PERFORMED AT :

Hiranandani Hospital-Vashi, Mini Seashore Road, Sector 10, Navi Mumbai, 400703 Maharashtra, India Tel: 022-39199222,022-49723322,

CIN - U74899PB1995PLC045956

Email: -





Page 2 Of











Male

PATIENT NAME: MR.KARAN LAKAVATH

CODE/NAME & ADDRESS : C000045507

FORTIS VASHI-CHC -SPLZD FORTIS HOSPITAL # VASHI,

MUMBAI 440001

REF. DOCTOR:

ACCESSION NO: **0022WK002241**PATIENT ID : FH.12814759

CLIENT PATIENT ID: UID:12814759

ABHA NO

AGE/SEX :31 Years

DRAWN :11/11/2023 11:59:00 RECEIVED :11/11/2023 11:58:55 REPORTED :11/11/2023 13:45:36

CLINICAL INFORMATION:

UID:12814759 REQNO-1605103 CORP-OPD

BILLNO-1501230PCR064255 BILLNO-1501230PCR064255

Test Report Status

**Final** 

Results

Biological Reference Interval

Units

**BIOCHEMISTRY** 

GLUCOSE, POST-PRANDIAL, PLASMA

PPBS(POST PRANDIAL BLOOD SUGAR)

88

70 - 140

mg/dL

METHOD: HEXOKINASE

Comments

NOTE:- POST PRANDIAL PLASMA GLUCOSE VALUES TO BE CORRELATE WITH CLINICAL, DIETETIC AND THERAPEUTIC HISTORY.

Interpretation(s)
GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin response & sensitivity etc. Additional test HbA1c treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc. Additional test HbA1c

\*\*End Of Report\*\*

Please visit www.agilusdiagnostics.com for related Test Information for this accession

(Atomatics

Dr. Akshay Dhotre, MD (Reg,no. MMC 2019/09/6377) Consultant Pathologist

Page 1 Of 1

View Details

View Report



Agilus Diagnostics Ltd.
Hiranandani Hospital-Vashi, Mini Seashore Road, Sector 10,
Navi Mumbai, 400703
Maharashtra, India
Tel: 022-39199222,022-49723322,
CIN - U74899PB1995PLC045956
Email: -



AVE  AVE  AVE  AVE  AVE  AVE  AVE  AVE	) H	(100,269)  on, age<55  convergent control of the co	* _	AS	92	
Sinus rhythm	( )	normal P axis, V-ra		20	EA	
	KAKAN LAKAVALD Male	Sinus rhythm	avr.	JAN	AAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA	

Hiranandani Healthcare Pvt. Ltd.

Mini Sea Shore Road, Sector 10-A, Vashi, Navi Mumbai - 400703.

Board Line: 022 - 39199222 | Fax: 022 - 39133220

Emergency: 022 - 39199100 | Ambulance: 1255

For Appointment: 022 - 39199200 | Health Checkup: 022 - 39199300

www.fortishealthcare.com | vashi@fortishealthcare.com

CIN: U85100MH2005PTC 154823 GST IN: 27AABCH5894D1ZG PAN NO: AABCH5894D

(For Billing/Reports & Discharge Summary only)





# DEPARTMENT OF RADIOLOGY

Date: 11/Nov/2023

Name: Mr. Karan Lakavath Age | Sex: 31 YEAR(S) | Male Order Station: FO-OPD

Bed Name:

UHID | Episode No: 12814759 | 65272/23/1501

Order No | Order Date: 1501/PN/OP/2311/135732 | 11-Nov-2023 Admitted On | Reporting Date: 11-Nov-2023 11:37:34

Order Doctor Name: Dr.SELF.

X-RAY-CHEST- PA

### Findings:

Both lung fields are clear.

The cardiac shadow appears within normal limits.

Trachea and major bronchi appears normal.

Both costophrenic angles are well maintained.

Bony thorax is unremarkable.

Highalu

DR. YOGINI SHAH DMRD., DNB. (Radiologist)

### Hiranandani Healthcare Pvt. Ltd.

Mini Sea Shore Road, Sector 10-A, Vashi, Navi Mumbai - 400703.

Board Line: 022 - 39199222 | Fax: 022 - 39133220 Emergency: 022 - 39199100 | Ambulance: 1255

For Appointment: 022 - 39199200 | Health Checkup: 022 - 39199300

www.fortishealthcare.com | vashi@fortishealthcare.com

CIN: U85100MH2005PTC 154823 GST IN: 27AABCH5894D1ZG PAN NO: AABCH5894D





Patient Name	:	Karan Lakavath	Patient ID	:	12814759
Sex / Age		M / 31Y 9M	Accession No.	:	PHC.6918674
Modality	1	US	Scan DateTime	:	11-11-2023 10:25:02
IPID No	:	65272/23/1501	ReportDatetime	:	11-11-2023 10:44:22

### USG - WHOLE ABDOMEN

IVER is normal in size and echogenicity. No IHBR dilatation. No focal lesion is seen in liver. Portal vein appears normal in caliber.

GALL BLADDER is physiologically distended. Gall bladder reveals normal wall thickness. No evidence of calculi in gall bladder. No evidence of pericholecystic collection. CBD appears normal in caliber.

SPLEEN is normal in size and echogenicity.

**BOTH KIDNEYS** are normal in size and echogenicity. The central sinus complex is normal. No evidence of calculi/hydronephrosis.

Right kidney measures 10.0 x 4.5 cm.

Left kidney measures 9.9 x 5.2 cm.

**PANCREAS**: Visualised head and body of pancreas appears normal. Rest of the pancreas is obscured due to bowel gas.

URINARY BLADDER is partially distended, limiting optimal evaluation of pelvis.

**PROSTATE** appears grossly normal and measures ~ 17.7 cc in volume.

No evidence of ascites.

### Impression:

No significant abnormality is detected.

DR. KUNAL NIGAM M.D. (Radiologist)